

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1644  
Examiner : Ronald B. Schwadron  
Serial No. : 09/155,514  
Filed : November 17, 1998  
Inventor(s) : Mie Kainoh  
: Toshiaki Tanaka

Customer No. 035811

Docket No.: 1102-98

Confirmation No.: 8751

Title : CHIMERIC PROTEINS, THEIR  
: HETERODIMER COMPLEXES, AND  
: PLATELET SUBSTITUTES

Dated: January 21, 2005

---

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN  
ACCORDANCE WITH 37 C.F.R. §§1.821-1.825**


Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In connection with the paper copy of the sequence listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. §1.821(g), does not include new matter; and
2. the computer readable form of the sequence listing, filed herewith in accordance with 37 C.F.R. §1.821(e), is identical to the paper copy of the sequence listing.

Respectfully submitted,

  
Paul Carango  
Reg. No. 42,386  
Attorney for Applicants

PC:rb  
(215) 656-3320



UNITED STATES DEPARTMENT OF COMMERCE  
U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

EXAMINER
----------

ART UNIT	PAPER
----------	-------

2001412

DATE MAILED:

**Please find below and/or attached an Office communication concerning this application or proceeding.**


**Commissioner for Patents**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

- a) The paper copy of the sequence listing lacks mandatory section <140>.
- b) The filing date in section <140> of the paper copy of the listing is incorrect and differs from that in the CRF (eg. it should be 11/17/98).
- c) The paper copy of the sequence listing was amended in the amendment filed 5/29/2001 wherein section <212> of SEQ. Ids 1,2 and 19 were changed to nucleic acid, yet the CRF recites DNA. In addition, said amendment changed portions of the listing to the preJuly 1998 format whilst the CRF is in the postJuly 1998 sequence rules format.
- d) In sequences 1,2,19,32-34, section <213> of the paper listing/  
CRF recites "homo sapien" when it should recite "artificial sequence". The aforementioned sequences are drawn to nucleic acids encoding proteins or said proteins wherein the molecules are Ig/integrin fusion proteins which are artificial sequences (eg. not found in nature).

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Ron Schwadron, Ph.D.  
Primary Examiner  
Art Unit 1644  
571 272 0851

  
RONALD B. SCHWADRON  
PRIMARY EXAMINER  
GROUP 1800-1644